Lovastatin modified release - Synthetic Biologics

Drug Profile

Lovastatin modified release - Synthetic Biologics

Alternative Names: SYN-010

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cedars-Sinai Health System
  • Developer Synthetic Biologics
  • Class Anti-inflammatories; Antihyperlipidaemics; Irritable bowel syndrome therapies; Naphthalenes
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Irritable bowel syndrome

Most Recent Events

  • 27 Jun 2017 Synthetic Biologics receives patent allowance for Lovastatin modified release in USA
  • 02 Mar 2017 Synthetic Biologics has patent pending for lovastatin modified release in USA and World (Synthetic Biologics Form 10-K, March 2017)
  • 02 Mar 2017 Synthetic Biologics has patent protection for lovastatin modified release in USA and World (Synthetic Biologics Form 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top